Ghent, Belgium-based Bruker said in a news release that the acquisition, for which financial terms were not disclosed, will strengthen its position as a leading NMI solutions provider in preclinical and translational imaging research.
The acquisitions will combine Bruker’s preclinical imaging products and global footprint with Molecubes’ modular benchtop Cubes systems, aiming to broaden the company’s NMI offering to further accelerate the worldwide adoption of preclinical NMI in academic medical centers and biopharma companies.
Molecubes develops and sells high-end PET, SPECT and CT Cubes systems, having installed more than 70 systems around the globe. Bruker believes the platforms complement its integrated, floor-standing preclinical small animal imaging systems.
“Nuclear molecular preclinical and translational imaging research are growing market segments, in which we are already recognized for high-performance, simultaneous PET/MR and PET/SPECT/CT instruments, and for our PMOD PET data analysis software,” Bruker BioSpin Preclinical Imaging Division President Dr. Wulf I Jung said in the release. “The acquisition of Molecubes adds scalable benchtop instruments to our portfolio for serving the NMI preclinical research community. The synergies between our and Molecubes’ research and development, applications and service teams is expected to benefit our combined NMI customers worldwide.”
Molecubes will remain an operational team within Bruker’s BioSpin Preclinical Imaging division and its customers may continue communications through existing channels.
“The high throughput of our unique scalable technology makes it an excellent tool to speed up drug discovery and translational research,” Molecubes CEO Roel Van Holen said. “Bruker has the reach to increase access to the Cubes in labs throughout the world, aligning with our joint mission to support the quality and speed of preclinical drug development and fundamental pathobiology research. Our team is looking forward to working within Bruker on research and innovative solutions for our existing and future customers.”
Filed Under: Drug Discovery, RD